Tags

Type your tag names separated by a space and hit enter

Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection.
J Infect Dis. 2004 Sep 15; 190(6):1119-26.JI

Abstract

BACKGROUND

Severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) is the principal etiologic agent of SARS. We analyzed serum samples obtained from 623 patients with SARS in Beijing, to determine whether infection with SARS-CoV can elicit neutralizing antibodies (NAbs).

METHODS

We developed a highly sensitive and safe neutralization assay using the SARS-CoV pseudotyped virus and used this assay to determine the titers of the NAbs in serum samples from patients with SARS.

RESULTS

We found that 85.9% of serum samples contained NAbs against SARS-CoV and that most of the NAb activities could be attributed to immunoglobulin G. The NAbs became detectable first at 5-10 days after the onset of symptoms, and their levels peaked at 20-30 days and then were sustained for >150 days. The serum samples could neutralize the pseudotype particles bearing the spike glycoproteins from different SARS-CoV strains, suggesting that the NAbs to SARS-CoV were broadly reactive.

CONCLUSIONS

NAbs to SARS-CoV are broadly elicited in patients with SARS and, according to their kinetics, may correlate with viral load during the early stages of the disease. These results suggest that it is possible to develop effective vaccines against SARS and that NAbs provide a potential strategy for treating patients with SARS.

Authors+Show Affiliations

Department of Cell Biology and Genetics, College of Life Sciences, Peking University, Beijing 100871, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15319862

Citation

Nie, Yuchun, et al. "Neutralizing Antibodies in Patients With Severe Acute Respiratory Syndrome-associated Coronavirus Infection." The Journal of Infectious Diseases, vol. 190, no. 6, 2004, pp. 1119-26.
Nie Y, Wang G, Shi X, et al. Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection. J Infect Dis. 2004;190(6):1119-26.
Nie, Y., Wang, G., Shi, X., Zhang, H., Qiu, Y., He, Z., Wang, W., Lian, G., Yin, X., Du, L., Ren, L., Wang, J., He, X., Li, T., Deng, H., & Ding, M. (2004). Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection. The Journal of Infectious Diseases, 190(6), 1119-26.
Nie Y, et al. Neutralizing Antibodies in Patients With Severe Acute Respiratory Syndrome-associated Coronavirus Infection. J Infect Dis. 2004 Sep 15;190(6):1119-26. PubMed PMID: 15319862.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection. AU - Nie,Yuchun, AU - Wang,Guangwen, AU - Shi,Xuanling, AU - Zhang,Hong, AU - Qiu,Yan, AU - He,Zhongping, AU - Wang,Wei, AU - Lian,Gewei, AU - Yin,Xiaolei, AU - Du,Liying, AU - Ren,Lili, AU - Wang,Jianwei, AU - He,Xiong, AU - Li,Taisheng, AU - Deng,Hongkui, AU - Ding,Mingxiao, Y1 - 2004/08/02/ PY - 2004/02/02/received PY - 2004/03/29/accepted PY - 2004/8/21/pubmed PY - 2004/10/8/medline PY - 2004/8/21/entrez SP - 1119 EP - 26 JF - The Journal of infectious diseases JO - J Infect Dis VL - 190 IS - 6 N2 - BACKGROUND: Severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) is the principal etiologic agent of SARS. We analyzed serum samples obtained from 623 patients with SARS in Beijing, to determine whether infection with SARS-CoV can elicit neutralizing antibodies (NAbs). METHODS: We developed a highly sensitive and safe neutralization assay using the SARS-CoV pseudotyped virus and used this assay to determine the titers of the NAbs in serum samples from patients with SARS. RESULTS: We found that 85.9% of serum samples contained NAbs against SARS-CoV and that most of the NAb activities could be attributed to immunoglobulin G. The NAbs became detectable first at 5-10 days after the onset of symptoms, and their levels peaked at 20-30 days and then were sustained for >150 days. The serum samples could neutralize the pseudotype particles bearing the spike glycoproteins from different SARS-CoV strains, suggesting that the NAbs to SARS-CoV were broadly reactive. CONCLUSIONS: NAbs to SARS-CoV are broadly elicited in patients with SARS and, according to their kinetics, may correlate with viral load during the early stages of the disease. These results suggest that it is possible to develop effective vaccines against SARS and that NAbs provide a potential strategy for treating patients with SARS. SN - 0022-1899 UR - https://www.unboundmedicine.com/medline/citation/15319862/Neutralizing_antibodies_in_patients_with_severe_acute_respiratory_syndrome_associated_coronavirus_infection_ L2 - https://academic.oup.com/jid/article-lookup/doi/10.1086/423286 DB - PRIME DP - Unbound Medicine ER -